Back
3rd Consortium Meeting, 20 Oct 2022
Since our previous consortium meeting in April, 2022, the final product tests required before the clinical studies are now almost completed and arrangements are put in place for the First in Human study, planned to start Q1-Q2 2023. Looking further into the future, we also discussed the next steps in exploration of the market and investment possibilities.